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Covalent modifications of histones, such as acetylation, methylation, and phosphorylation, and other epigenetic modulations of the
chromatin, such as methylation of DNA and ATP-dependent chromatin reorganisation, can play a major part in the multistep process
of carcinogenesis, with far-reaching implications for human biology and human health. This review focuses on how aberrant covalent
histone modifications may contribute to the development of a variety of human cancers, and discusses the recent findings with regard
to potential therapies.
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CHROMATIN REMODELLING
Eukaryotic DNA is intimately associated with a family of small,
basic histone proteins, to form a highly ordered and condensed
protein:DNA complex termed chromatin. Generally, two different
forms of chromatin have been described; heterochromatin is
tightly compacted and associated with transcriptionally silent
genomic regions, whereas euchromatin has a more open
conformation and tends to support transcription (reviewed in
Wolffe and Kurumizaka, 1998).
The fundamental unit of the chromatin polymer is the
nucleosome, which consists of approximately 147 base pairs of
DNA wrapped around an octamer of histone core proteins. This
octamer is composed of two copies of each H2A, H2B, H3, and H4,
or in some instances, specialised natural variants of these proteins.
From this fundamental chromatin unit, N- and, in some cases, C-
termini of core histones protrude from this core structure and
contact adjacent nucleosomes in a higher-order structure whose
details remain elusive (Luger et al, 1997). It is now becoming clear
that histone-modifying enzymes can alter the structure of these
domains and/or influence the binding of ‘effector’ molecules that,
in turn, affect patterns of gene expression. Aberrant activity or
mis-targeting of these chromatin-modifying activities is proving to
have unexpected links to carcinogenesis.
Remodelling of chromatin can be achieved in several different,
but interconnected, ways: (1) covalent modification of histones, (2)
exchange of ‘generic’ core histones with histone variants, (3)
disruption of the basic nucleosome structure and histone DNA
contacts, and (4) modification of the DNA itself. As mentioned
above, tail domains of histones are subject to a diverse array of
covalent modifications that include: lysine acetylation, lysine and
arginine methylation, serine and threonine phosphorylation, ADP-
ribosylation, ubiquitination, sumolation, and, likely, other yet
unknown or poorly appreciated modifications.
Histone acetylation, arguably the best-studied histone modifica-
tion, occurs at the e amino groups of evolutionarily conserved,
often invariant, lysine residues most often located in tail domains.
Levels of acetylation of the core histones result from the steady-
state balance between the opposing activities of histone acetyl-
transferases (HATs) and histone deacetylases (HDACs). In general,
increased levels of histone acetylation (hyperacetylation) are found
in more decondensed euchromatin, whereas decreased levels of
acetylation (hypoacetylation) are a characteristic of more con-
densed heterochromatin (Strahl and Allis, 2000; Turner, 2000;
Fischle et al, 2003b).
Methylation of histones can occur on lysine and arginine
residues, giving the cell another layer of regulatory options (in
some cases on lysine residues, which are well known to also be
acetylation sites; for example, lysine 9 in histone H3). In addition,
lysines can be mono-, di-, or tri-methylated, whereas arginines can
be mono- or di-methylated (symmetrically or asymmetrically),
thus greatly extending the complexity of histone modification-
dependent gene regulation. Current evidence suggests that histone
arginine methylation is more dynamic, correlating well with gene
activation and its loss from target arginines in H3 and H4, with
gene inactivation (reviewed in Stallcup, 2001; Bannister et al, 2002;
Davie and Dent, 2002). In contrast, lysine methylation appears to
be a more stable mark, with what appears to be a more
complicated readout (reviewed in Zhang and Reinberg, 2001;
Lachner, 2002). For instance, as depicted in Figure 1A, methylation
of lysine 4 in histone H3 correlates with gene activation, whereas
methylation of lysines 9 and 27 in histone H3 correlates with
repression (reviewed in Bannister et al, 2002; Fischle et al, 2003b).
These marks are ‘written’ by histone methyltransferases (HMTs),
many of which contain a conserved SET (Su(var)3–9, Enhancer-
of-zeste, Trithorax) domain (reviewed in Schneider et al, 2002).
Insights into SET domain structure and mode of catalysis are
beginning to emerge (Min et al, 2002). ‘ON’ and ‘OFF’ methyl
marks are ‘read’ by chromodomain-containing proteins, such as
heterochromatin protein 1 (HP1) and Polycomb (Pc) (Figure 1A),
and it is becoming clear that these proteins specifically recognise Received 29 September 2003; accepted 11 November 2003
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et al, 2003c).
Phosphorylation is another important and long-appreciated
histone modification that is often associated with chromosome/
chromatin condensation that includes mitosis, meiosis, apoptosis
and DNA damage, events regulated by different histone kinases
(for example, members of the Aurora/AIK family; reviewed in
Fischle et al, 2003a). Histone phosphorylation is also closely
correlated with chromosome decondensation events (such as the
immediate-early response to mitogens), suggesting a ‘split
personality’ for certain modifications that remains to be fully
understood (for example, at serine 10 in H3) (Cheung et al, 2000).
The histone ‘code’ hypothesis (Strahl and Allis, 2000; Fischle
et al, 2003b) has been put forward that may explain the seemingly
complex nature of reported patterns of histone modification
readouts. Formally, this hypothesis states that one modification or
specific combinations of histone modifications can affect distinct
downstream events by altering the structure of the chromatin and/
or generating a binding platform for protein effectors that can
specifically recognise the modification(s) and initiate gene
transcription or repression. Alternative views for how distinct
patterns of histone modifications may coordinate distinct biolo-
gical readouts have also been expressed (Schreiber and Bernstein,
2002; Kurdistani and Grunstein, 2003).
The finding that cells contain alternative, more specialised
versions of the four canonical core histones is well documented.
Numerous histone variants have been described in all eukaryotes
for all histone classes except histone H4. While poorly appreciated
and poorly understood, histone variants afford the cell a chance to
alter the primary sequences contained within the nucleosome.
Active replacement of histone variants into ‘normal’ nucleosomes
may, in turn, alter the regulatory options available, including
choices of post-translational modifications. For example, in several
cases, replacement of serine for alanine distinguishes the H3
histone from that of a H3 variant, H3.3 (Figure 1A). These
differences suggest alterations in phosphorylation that may reflect
functional differences between the two histones (Ahmad and
Henikoff, 2002). In keeping, a specialised H2A variant, H2A.X, has
recently been shown to act as if it is a ‘caretaker’ of our genome
upon DNA damage (Figure 4B,C; Bassing et al, 2003; Celeste et al,
2003). As histone variants also are enriched in other critical
regions of the genome, such as centromers and inactive X
chromosome (reviewed in van Leeuwen and Gottschling, 2003),
it seems likely that histone variants themselves hold many more
secrets.
ATP-dependent chromatin remodelling multi-protein com-
plexes, such as SWI/SNF, noncovalently alter or disrupt the
nucleosome structure, promoting transient loosening of DNA–
histone contacts and facilitating the binding of transcription
factors (Muchardt and Yaniv, 1999). Emerging evidence suggests
that some of these ATP-dependent remodellers may function to
shuffle histone variants into and out of chromatin (Figure 4A)
(Mizuguchi et al, 2003).
Outside the covalently marking histone proteins in localised
genomic locations, such as hyperacetylating specific promoter
elements or other such upstream activating sequences, it appears
that other long-range ‘indexing’ systems also operate to mark the
epigenome. For example, using chromatin immunoprecipitation
(ChIP) assays and site-specific methylation antibodies, elegant
studies have shown that lysine 4 methylation vs lysine 9
methylation in histone H3 can mark relatively large chromosomal
domains (about 25–50kb) with ‘active’ vs ‘inactive’ signatures
often interrupted by sharp transitions or boundaries that are
poorly understood (reviewed in Jenuwein and Allis, 2001; Zhang
and Reinberg, 2001; Felsenfeld and Groudine, 2003). Moreover, as
depicted in Figure 1B, it appears that the repressive lysine 9
methylation mark in histone H3 is a dominant histone mark in
mammalian histones (‘OFF’), whereas in lower eukaryotes
methylation of lysine 4 in H3 (‘ON’) dominates (Briggs et al,
2001). This suggests that epigenetic mechanisms exist that lead to a
silencing default or ground state in higher organisms. Figure 2
shows some examples of how the cell may achieve gene silencing
using epigenetic-based mechanisms. One possibility to repress
gene transcription, as shown in Figure 2A, is the removal of acetyl
groups from H3 (activation mark) by HDACs, a process that can
be inhibited by HDAC inhibitors (HDACi). Unmodified lysine 9 is
in turn methylated by HMTs by converting S-adenosylmethionine
(SAM) to S-adenosylhomocysteine (SAH). This metabolism can be
directly influenced by dietary take-up, and aberrant SAM/SAH
ratio can affect health and potentially contribute to carcinogenesis
(Huang, 2002). HP1 recognises this ‘OFF’ mark and maintains gene
silencing.
Not only do histone modifications influence chromatin struc-
ture, but modifications of the DNA itself can also lead to
remodelling of chromatin and consequently result in gene
silencing. DNA methylation results from the activity of a family
of DNA methyltransferase (DNMT) enzymes, which catalyse the
addition of a methyl group to cytosine residues at CpG (adjacent
cytosine and guanine nucleotides) islands, also by converting SAM
to SAH (see Figure 2B). A family of proteins with a methyl-binding
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Figure 1 ‘Writing’ and ‘reading’ of certain covalent marks in human
histone H3 and H3.3 variant. (A) Dominant methyl marks are found on
lysines 4, 9, and 27 in histone H3, all adjacent to threonine or serine,
potential phosphomark carriers (Fischle et al, 2003a). Methylation of lysine
4 is generated by the SET domain of MLL, and is connected to gene
activation of ceratin target genes (green¼‘ON’ mark) (Milne et al, 2002).
Protein(s) that ‘read’ this mark are not yet identified. Marks that correlate
with gene silencing are methylation of lysines 9 and 27, generated by the
HMTs SUV39H1 and EZH2, respectively (red¼‘OFF’ marks). ‘Readers’ of
these repressive marks are HP1 for lysine 9 methylation and Pc for lysine 27
methylation (Fischle et al, 2003c). Serines, adjacent to lysines 9 and 27, are
shown to be phosphorylated by Aurora B kinase (orange), and might play a
role in preventing ‘readers’ from recognising methyl marks. It is not yet
known if threonine 3 is also a phospho mark (orange circle). Sequence
alignment of the N-termini of H3 with H3.3 variant shows an almost
identical sequence, except that alanine 31 in H3 is replaced by serine in
H3.3, another potential phospho mark. (B) Lower eukaryotes maintain an
epigenetic active or permissive state, whereas higher eukaryotes show an
epigenetic repressive phenotype. Histone H3 from yeast and Tetrahymena
are strongly methylated at lysine 4 (‘ON’ mark), but not at lysine 9 (‘OFF’
mark). The opposite was observed for H3 in chicken and humans, where
lysine 9 was strongly methylated, but not lysine 4 in H3 (Briggs et al, 2001).
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shown to associate with large protein complexes containing
HDACs and chromatin-remodelling activities. As a result, histones
are deacetylated and gene transcription is most often repressed. It
has also been suggested that DNA methylation could lead to gene
silencing by MBD proteins that recruit HMTs, which methylate
lysine 9 in histone H3 and subsequently repress gene transcription
(Figure 2C) (reviewed in Rice and Allis, 2001; Brown and
Strathdee, 2002).
More recently, genetic links between histone methylation,
notably tri-methylation at lysine 9 in histone H3, and DNA
methylation have appeared in organisms as diverse as fungi,
plants, and mice (Hashimshony et al, 2003; Lehnertz et al, 2003).
Thus, histone methylation and deacetylation and DNA methylation
have direct and indirect links that connect each of them to each
other and to the readout of higher-order chromatin structures. The
breakthrough findings that histone methylation, notably lysine 9
methylation in histone H3, may also be ‘guided’ by small
heterochromatin-associated RNAs by a mechanism that remain
unclear (see Figure 2D) suggest that the cell has invested
considerable energy in covalently marking what is now referred
to as the ‘epigenome’ (reviewed in Grewal and Moazed, 2003). We
and others favour the view that histone deacetylation, histone
methylation, DNA methylation and the production of small RNAs,
all work together in various orders to bring about an efficient silent
state (Grewal and Moazed, 2003). Remarkably, these epigenetic
silencing mechanisms can be targeted to ectopic genes, thereby
marking chromatin in such a way that this silencing state is
inherited over many cell generations (Snowden et al, 2002;
Ayyanathan et al, 2003).
On the other hand, epigenetic mechanisms have also evolved to
ensure that specific genes are not only silenced, but also activated
at appropriate times during the cell cycle or during development.
Figure 3 shows some examples of the coordinated interplay
between kinases, HATs and HMTs marking the chromatin in such
ways that genes are transcribed. As shown in Figure 3A, the
epigenetic ‘language’ of gene activation contains ‘ON’-marks like
lysine 4 methylation and histone hyperacetylation. But how cells
manage to switch from repressive chromatin that contains, for
example, lysine 9 methylation in histone H3, to an active state with
nucleosomal ‘ON’ marks is not known. A new theory, the so-called
binary ‘switch hypothesis’ is based on the observation that the best
studied methyl marks in the H3 tail (lysine 4, 9, and 27) are all
adjacent to serine or threonine (potential phospho marks), and
discusses the arising regulatory possibilities with regard to gene
repression and activation (see Figure 1A; Fischle et al, 2003a). This
concept proposes that phospho marks permit the docking of
methylmark ‘readers’, allowing gene activation by at least two
possible mechanisms. In the first scenario, see Figure 3B,
phosphorylation of serine 10 in H3 interferes with the blading of
HP1 to the methyl mark on lysine 9, and lead to an only temporary
switch from repression to activation by additional histone
acetylation. This process can be converted back through a more
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Figure 2 Epigenetic modifications leading to gene silencing. (A) Gene
repression through histone methylation. Histone deacetylase deacetylates
lysine 9 in H3, which can then be methylated by HMTs. Methylated lysine 9
in H3 is recognised by HP1, resulting in maintenance of gene silencing. (B)
Gene repression involving DNA methylation. DNA methyltransferases
methylate DNA by converting SAM to SAH, a mechanism that can be
inhibited by DNMT inhibitors (DNMTi). MBPs recognise methylated DNA
and recruit HDACs, which deacetylate lysines in the histone tails, leading to
a repressive state. (C) Interplay between DNMTs and HMTs results in
methylation of DNA and lysine 9 in H3, and consequent local
heterochromatin formation. The exact mechanism of this cooperation is
still poorly understood. (D) Specific gene repression by small RNAs
(sRNAs). Transcription of repetitive DNA sequences lead to double-strand
RNA (dsRNA) generation by still poorly understood mechanisms, and
dsRNA is later processed to sRNAs. sRNAs associate with and recruit
HMTs to the complementary DNA sequence, where HMTs locally
methylate lysine 9 in H3. Methylated lysine 9 is recognised by ‘HP1’ that
forms a complex with HMTs to spread the repressive mark to other
histones, until reaching a boundary. ‘Writers’ and ‘readers’ of DNA
epigenetic marks are shown in blue, and proteins involved with repressive
histone marks are depicted in red. Tail length has been exaggerated for
clarity.
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removed easily. To switch from a repressive to a stable active state,
another possibility can be envisaged. As depicted in Figure 3C, a
not yet identified histone demethylase (HDM) may recognise the
phospho mark on serine 10 and erase the repressive methylmark
from lysine 9, thereby allowing HATs to acetylate lysine 9,
producing an activation -mark. Alternatively, as depicted in
Figure 3D, repressive-marked histones may be exchanged with
newly synthesised histones or histone variants that can be
modified with activation marks, such as methylation of lysine 4
and histone hyperacetylation.
The pathways depicted in Figures 2 and 3 are proposed to take
place in normal cells, leading to appropriate gene silencing and
activation. It remains unclear to what extent these pathways go
awry in the progression of human neoplasia. However, as none of
these pathways shown involve DNA mutation, understanding the
fundamental mechanisms of epigenetic silencing promises to
afford opportunities to de-silence (or de-activate) genes that may
have been inappropriately silenced (or activated) during transfor-
mation and tumour progression. Below, we highlight some of the
more clear examples where enzymes that ‘write’, or protein
effectors that ‘read’ the covalent language of histone modifications,
have been linked to human cancer. Exciting recent developments
in this field are beginning to surface and show remarkable promise
in clinical trials, as epigenetic forms of dysfunctional pathways are
uncovered in human cancer and experimental therapeutic
strategies are advanced. Our review intends to stay centred on
epigenetic-based mechanisms, pathways, and players, many of
which are superficially depicted in all figures. Interested readers
are encouraged to refer to other excellent reviews on emerging
chromatin links to human biology and disease, notably cancer
(Chakraborty et al, 2001; Klochendler-Yeivin and Yaniv, 2001;
Beaudet, 2002).
CANCER AND EPIGENETICS
Epigenetic-based mechanisms that lead to carcinogenesis can be
divided into at least three different categories: (1) repression of
normally active genes, for example tumour-suppressor genes,
generated by the single or combined activities of HDACs, HMTs,
DNMTs, and SWI/SNF, (2) activation of normally silent genes, for
example, oncogenes, where HAT and HMT activities, and SWI/SNF
proteins are involved, and (3) replacement of core histones with
specifically modified histone variants.
Aberrant gene repression and cancer
As depicted in Figure 2, the interplay of different histone
modification and DNA methylation enzymes leads to transcrip-
tional gene repression. Deregulation of this cooperation or mis-
targeting of these enzymes can lead to neoplasia, and a few
examples will be discussed below.
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Figure 3 Epigenetic modifications leading to gene activation. (A) Setting
‘ON’ marks in histone H3 to activate gene transcription. Lysine 4 in H3 is
methylated by HMT (for example MLL) and lysine 9 is acetylated by HAT,
allowing genes to be transcribed. It is not known, if HMTs and HATs have a
direct connection to each other. (B) In the postulated ‘switch’ hypothesis
(Fischle et al, 2003a), phosphorylation of serines or threonines adjacent to
lysines displaces histone methyl-binding proteins, accomplishing a binding
platform for other proteins with different enzymatic activities. For example,
phosphorylation of serine 10 in H3 may prevent HP1 from binding to the
methyl mark on lysine 9. Other lysines in H3 may be acetylated by HATs,
therefore overwriting the repressive lysine 9 methyl mark and allowing
activation. (C) Although there is no HDM identified to date, one can
speculate that, if this enzyme exists, serine 10 phosphorylation in H3, for
example, by Aurora kinases, can lead to recruitment of HDMs that in turn
demethylate lysine 9 in H3. Histone acetyltransferases might then acetylate
lysine 9 and HMTs methylate lysine 4, resulting in the loosening of the
chromatin structure and allowing gene transcription. (D) Repressive-
marked histones are exchanged with unmodified (or active) counter parts
(dark circles) that are then acetylated at lysine 9 by HATs and methylated
at lysine 4 in H3 by HMTs, for example, MLL, leading to gene activation.
Proteins involved with repressive histone marks are depicted in red,
‘writers’ and ‘readers’ of histone activation marks are shown in green,
kinases are orange and phospho marks are depicted as orange circles.
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is generated by the activity of HDACs and results in silencing of
genes (see Figures 2A,B). Deregulation of HDAC activity and
resulting histone deacetylation at normally active sites can lead to
cancer.
The acute myeloid leukaemia gene 1 (RUNX1/AML1/CBFA2) is
one of the most frequent targets for chromosomal translocations in
leukaemia. The AML1 protein binds to the co-repressors Groucho/
transducin-like enhancer (TLE) and Sin3, and also the HAT p300/
CBP complex (Javed et al, 2000), and guides their activity to AML
target genes. Therefore, depending on the specific target gene,
AML1 is capable of functioning as both a transcriptional activator
and repressor.
One common oncogenic event is the t(8;21) translocation that
fuses the DNA-binding domain of AML1 with ETO (MTG8). ETO,
the mammalian homologue of Drosophila Nervy, is a nuclear
phosphoprotein that is expressed in haematopoietic progenitors.
ETO interacts with multiple HDACs and Sin3, N-CoR, and SMRT
co-repressors. The AML1–ETO fusion protein localises to AML1
target genes, where it, in contrast to the wild-type AML1 protein,
actively suppresses transcription via the co-repressors N-CoR/
Sin3/HDAC1, directly. Since AML1 is required for differentiation
of haematopoietic cells, AML1–ETO expression leads to a block in
myeloid development and leukaemic transformation (reviewed in
Jones and Saha, 2002). Interestingly, point mutations in AML1
resulting in haploinsufficiency are associated with familial
thrombocytopenia and a markedly increased risk for the develop-
ment of acute myeloid leukaemia (Song et al, 1999).
RB An excellent example of the cooperate interplay of HDACs,
HMTs, and SWI/SNF (see Figure 2A) in carcinogenesis is the
deregulation of the tumour suppressor retinoblastoma protein
(Rb) pathway, which is mutated in a majority (90%) of human
solid tumours. Rb pathway defects include gain-of-function
mutations of the cyclin-dependent kinase cdk4/cyclin D, which
activates Rb through phosphorylation, and loss-of-function muta-
tions of p16 and Rb. Rb regulates cell proliferation by controlling a
set of transcription factors (the E2F family of proteins) that
activate genes involved in the G1/S cell cycle transition. Hypopho-
sphorylated Rb inactivates E2F in early G1 phase and becomes
hyperphosphorylated during G1/S transition, resulting in the
release and activation of E2F (Hanahan and Weinberg, 2000).
At least two mechanisms contribute to the inactivation of E2F.
Firstly, Rb binds to the transactivation domain of E2F and
subsequently prevents E2F from association with promoter
regions, resulting in the silencing of its target genes. Secondly,
Rb can be targeted to specifc sites through association with E2F,
thereby actively repressing transcription by recruiting HDAC1 and
SWI/SNF. Histone deacetylase 1 binding to the Rb–E2F complex
leads to the transcriptional silencing of cell cycle-related genes,
including cyclin E. BRG1/BRM, a component of SWI/SNF, is also
found to be associated with Rb, and this complex cooperatively
induces G1/S cell cycle arrest. The Rb–BRG1/BRM complex seems
to be required for the repression of cyclin A and cdk2 genes, which
are important for G2/M phase transition, but not cyclin E, which is
necessary for S-phase entry. This suggests that distinct histone
remodelling and modification complexes may be required for Rb
to repress different target genes (reviewed in Harbour and Dean,
2000). Notably, loss of integrase interactor 1 (INI1), a core
component of the SWI/SNF complex, is a characteristic feature of
some human tumours including rhabdoid and primitive CNS
tumours (Sevenet et al, 1999). In addition, mutations in Brg-1 have
been identified in a variety of human tumours (reviewed in
Muchardt and Yaniv, 2001). Rb has been shown to interact with the
human homologue of Polycomb (PcG) HPC2, and the HMT
Suv39H1, both of which seem to play a role in transcriptional gene
repression by methylation of lysine 9 and/or 27 in histone H3
(Dahiya et al, 2001; Nielsen et al, 2001). These data suggest an
important role for Rb family proteins in linking sequence-specific
transcription factors with a variety of histone remodelling and
modification enzymes, an observation that may also explain why
Rb is a favourite target for mutations in cancer.
EZH2 Mammalian PcG proteins are HMTs, and can repress
transcription by at least two different mechanisms. (1) The PcG
complex that contains EED and enhancer of zeste homolog (EZH)
proteins 1 and 2 recruits HDACs and represses transcription of
target genes by the combinatory action of local histone methyla-
tion and deacetylation. (2) The Polycomb repressive complex 1
(PRC-1) contains polycomb 2 (HPC2), polyhomeotic (HPH), BM1
and Ring-finger protein 1 (RING1) proteins and associates with the
SWI/SNF chromatin remodelling complex, and negatively regu-
lates chromatin accessibility (Shao et al, 1999).
The Drosophila E(Z) protein is shown to methylate lysines 9 and
27 in H3, and causes stable changes in the chromatin, leading to
the repression of target genes (Su et al, 2003). Overexpression of
the human E(Z) homologue EZH2 has been observed in prostate
cancer and lymphomas, and is linked to increased cell proliferation
(Sellers and Loda, 2002; Varambally et al, 2002). Although EZH2
target genes have not been directly linked to cancer development,
evidence for EZH2 function in at least B-cell development is
beginning to emerge. Mice deficient for EZH2 showed impaired
early B-cell development and decreased rearrangement of the
immunoglobulin heavy chain (IgH). Since EZH2 has been shown
in this study to specifically methylate lysine 27 in H3, it is plausible
that EZH2 absence reduces both basal and interleukin-7-induced
histone H3 lysine methylation, although the exact mechanism(s)
remains elusive (Su et al, 2003). Since EZH2 plays a role in B-cell
development in mice, it will be interesting to see, if human
lymphomas show an increased methylation of lysine 27 (and
possible lysine 9) in histone H3 at EZH2 target genes. And, if so, is
the resulting repression of these genes oncogenic?
DNA methylation As described above, DNA methylation is an
additional mechanism to silence genes (see Figures 2B,C), and
considerable work has been invested to study the connection
between aberrant DNA methylation and cancer.
At the early stage of neoplasia, cells develop genome-wide
hypomethylation of DNA. Later on, promoter regions of several
tumour-suppressor genes, such as p16 and BRCA1, are hyper-
methylated, leading to downregulation of transcription. Numerous
pathways are affected by aberrant DNA hypermethylation,
including cell cycle, DNA repair, and hormonal responses, and
therefore alter the perfect epigenetic cell equilibrium. The
mechanisms leading to this oncogenic profile of hypermethylation
and different numerous tumours are currently not understood
(Bachman et al, 2003).
The other remarkable characteristic of neoplasias is the early
occurrence of a global genomic hypomethylation. This loss of DNA
methyl marks is achieved mainly by hypomethylation of exons and
introns of gene-rich regions and repetitive DNA sequences. This
phenomena is also not well understood, but may contribute to
carcinogenesis by several mechanisms, such as loss of imprinting,
chromosomal instability, and reactivation of transposable elements
(reviewed in Esteller, 2003). Due to limited space, we are not able
to give a more detailed overview about this topic, and we
encourage interested readers to refer to other excellent reviews
on the connection of DNA methylation and cancer (Dunn, 2003;
Jaenisch and Bird, 2003; Laird, 2003; Szyf, 2003).
Aberrant gene activation and cancer
Not only does the repression of genes by the activity of HDACs,
HMTs, DNMTs, and SWI/SNF have important implications in
neoplasia, the transcriptional activation of genes at unusual
times in cell differentiation and development by the activities of
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cancer. One excellent example is MLL, which will be discussed
below.
MLL Lysine 4 methylation in histone H3 is often regarded as an
‘activating’ epigenetic mark that is abundant in lower eukaryotes,
but only sparsely presented in mammals (see Figure 1B) (Briggs
et al, 2001). Interestingly in yeast, Set1 is solely responsible for
introducing lysine 4 methylation in H3. The Set1 SET domain
mostly resembles the Drosophila ‘positive’ memory protein
trithorax, and the mixed-lineage leukaemia (MLL/HRX/acute
lymphocytic leukaemia (ALL)-1) SET domain in humans.
In cells with normal amounts of wild-type MLL protein, the
overall MLL activity appears to be dependent on the balance
between activation and repression. On the one hand, MLL has been
reported to repress transcription by recruiting PcG proteins and/or
HDAC1 (Xia et al, 2003). On the other hand, MLL’s SET domain
can generate the ‘ON’ methyl mark on lysine 4 in H3 (Milne et al,
2002) and associates with INI1 (Rozenblatt-Rosen et al, 1998), and,
additionally, MLL is shown to interact with the HAT CBP (Ernst
et al, 2002). These partners and intrinsic activities lead to an open
chromatin structure and transcriptional activation of MLL target
genes in early development.
One of the best understood targets of MLL are the clustered
homeobox (Hox) genes, which play important roles in axial
morphogenesis, patterning, and haematopoetic differentiation
(Krumlauf, 1994). Individual Hox gene expression is high in
progenitor cells, and is downregulated during differentiation and
maturation. Expression of Hox genes (e.g. Hoxa9) is upregulated
in human leukaemias carrying MLL rearrangements, and it has
been shown recently that transformation by MLL fusion proteins
requires Hoxa7 and Hoxa9 (Ayton and Cleary, 2003), indicating
that these are pivotal for MLL-associated leukaemogenesis.
The MLL gene is involved in many chromosomal translocations
associated with ALL and AML (reviewed in Ayton and Cleary,
2001). In case of leukaemogenic MLL fusions, the balance of
MLL’s repression and activation functions might be disturbed.
Rearrangements of MLL that occur in leukaemia consistently
delete the C-terminus, containing plant homeodomain (PHD)
fingers, CBP-binding domain, and SET domain, and replace these
sequences with one of over 40 different translocation partners that
in general share little sequence homology. Since MLL fusion
proteins lack the SET domain to methylate lysine 4 in H3
(‘ON’ mark) and CBP-binding domain, it is unclear how MLL
fusions lead to Hox gene overexpression and subsequently to
leukaemia. Interestingly, all MLL fusion proteins also delete the
PHD finger domain, which binds to Cyp33, a cyclophilin family
member (Fair et al, 2001). In wild-type cells, Cyp33 binding to
MLL increases the association of HDAC1 to MLLs repression
domain. In the context of MLL fusion proteins, HDAC binding to
the repression domain may not be as strong, due to the lack of
PHD finger domain and loss of Cyp33 interaction. This may also
affect the binding of PcG proteins, ultimately altering the balanced
function of the protein, leading to the activation of normally
transcriptional silent genes.
Another way to explain the altered activity of rearranged MLL
might be found in the different MLL fusion partners and their
biological functions, because some play a role in chromatin
remodelling processes themselves. Fusions of MLL with, for
example, CBP, t(11;16)(q23;p13.3), retain the HAT domain of
CBP, and might lead to leukaemia by promoting histone
acetylation of genomic regions targeted by MLL, and allowing
transcriptional activation (Sobulo et al, 1997). Another fusion
partner of MLL is ENL, a subunit of the SWI/SNF complex. MLL–
ENL fusion proteins, t(11;19), associate and cooperate with SWI/
SNF complexes to activate transcription of the Hoxa7 promoter
(Nie et al, 2003). Fusion of MLL to AF10, t(10;11)(p12;23), creates a
protein that could interact with GAS41, a member of the basal
transcription factor complexes TFIID and TFIIF, and an interact-
ing component of SWI/SNF, and potentially activate Hox
gene expression by aberrant chromatin remodelling (Debernardi
et al, 2002). Intriguingly, dimerisation of the truncation
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Figure 4 Histone variants and their importance in diverse biological
pathways. (A) Histone variants, such as H3.3, shown in Figure 1A, are
integrated into nucleosomes by a yet not understood mechanism. New
data suggest that an ATP-dependent chromatin remodelling complex
related to SWI/SNF is involved in the replacement of histones with their
variant counterparts (shown here is the exchange of H2A with the variant
H2A.X (depicted in blue)). (B) Importance of the histone variant H2A.X
(depicted in blue) in DNA damage repair. Upon DSB, serine 139 in H2A.X
is phosphorylated by phosphatidylinositol 3-kinase, a mark that is
recognised by a complex of DNA repair proteins (DRP) that restore the
structure of the DNA. After successful DSB repair, serine 139 is
dephosphorylated by a yet unknown phosphatase. (C) Deficiency of
histone variant H2A.X (blue circle) has critical implications for genomic
stability. As shown in Figure 4B, H2A.X is important in DNA damage repair
and needs p53 to arrest the cell to allow DSB repair. Alternatively, if the
DNA damage is severe, p53 activates the apoptosis pathway, preventing
thereby mutations and/or chromosome translocations (left site). Loss of
both H2A.X and p53 can lead to chromosomal rearrangements after DSB
and result in cancer (right site).
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oncogenesis that also results in Hox gene upregulation (Martin
et al, 2003; So et al, 2003). Collectively, these data suggest that
MLL can activate genes at inappropriate times by mis-targeting
histone mark ‘writers’, consequently modifying the chromatin to
allow gene activation.
Histone variants and cancer
Many efforts have been invested to study the products and
functions of chromosomal rearrangements and translocations in
leukaemia and lymphoma. Mammalian cells, in general, are
engineered to keep the genome stable, but little is known about
how cells achieve their daunting task to prevent oncogenic events.
Not only are proteins with enzymatic activity that covalently
modify histones or DNA important, but the identity of the histones
themselves might also play an important role in gene regulation.
One excellent example of this is provided with the H2A histone
variant H2A.X. Recent studies show that DNA damage-induced
phosphorylation of H2A.X may be critical to maintain genomic
stability. Thus, in addition to alter the gene expression profile
without changing the primary DNA sequence, epigenetic factors
also regulate genomic integrity (see Figure 4).
H2A.X Six minor variants of human H2A histones have been
reported to date. H2A.X, which represents roughly 10–15% of total
H2As in human chromatin, is incorporated into the genome
seemingly randomly, and has a longer C-terminus than all other
H2A species. Many studies demonstrated that serine 139 of the
SQEY motif in the C-terminus is hyperphosphorylated in response
to DNA double-strand breaks (DSBs) upon DNA damage, and
during meiotic recombination, DNA replication, and V(D)J
recombination at the T-cell receptor and immunoglobulin loci.
As shown in Figure 4B, H2A.X is phosphorylated in nucleosomes
adjacent to DSBs and protein factors involved in DNA repair and
signalling pathways are recruited to this site (Paull et al, 2000;
Redon et al, 2002).
Despite the observation that H2A.X-deficient mice have
increased genomic instability, they are not prone to tumour
development (Celeste et al, 2002). But when crossed onto p53-
deficient backgrounds, H2A.X deficiency accelerates the lympho-
cytic tumour development observed in p53-deficient mice (Bassing
et al, 2003; Celeste et al, 2003). As depicted in Figure 4C, this
acceleration is correlated with an increased translocation rate in
these tumours, but the contributing molecular mechanism(s)
remains to be identified. H2A.X seems to function as a genomic
‘caretaker’ by helping other factors, such as p53, to prevent
erroneous repair of damaged DNA (reviewed in Downs and
Jackson, 2003). Interestingly, the genomic locus for human H2A.X,
11q23.3, has been mapped to a region that is frequently altered in
human cancers, possibly implicating similar functions in humans
(Monni and Knuutila, 2001).
CONCLUSION AND PERSPECTIVE
Epigenetics can be defined as heritable changes in gene expression
that operate outside of changes (for example, mutations) in DNA
itself. Collective studies, reviewed in part here, underscore the fact
that all transcription-based regulatory phenomena must take place
within a chromatin infrastructure; chromatin is the physiological
template of the genome. Emerging evidence now indicates that cell
cycle progression, DNA replication, DNA repair, programmed
DNA rearrangements, imprinting phenomena, germ-line silencing,
developmentally coordinated stem cell divisions, and chromosome
stability and identity are all influenced by such epigenetic
alterations of chromatin structure. These discoveries have revealed
a fundamental and critical regulatory system beyond the sequence
information of our genetic code that is maintained in histone
proteins as major carriers of epigenetic information (Felsenfeld
and Groudine, 2003). Based on the recent progress, it seems likely,
if not certain, that epigenetics, in part dictated through a covalent
‘language’ operating in the histone proteins, will touch upon all
aspects of biology with far-reaching implications for human
biology and disease, notably cancer.
In support, emerging evidence lend support to an emerging view
that aberrant chromatin remodelling events play an important role
in carcinogenesis; a growing number of HDAC and DNMT
inhibitors (HDACi and DNMTi, respectively) are being developed
for cancer treatment (see Figure 2). Suberoylanilide hydroxamic
acid (SAHA), to name only one HDACi, is currently in clinical
trials for a variety of solid tumours and haematologic malig-
nancies, and shows promising results, although the exact
mechanism(s) and targets of its anticancer function remain
unclear.
Many tumours are found to have aberrantly hypermethylated
CpG islands, a finding that is applicable for the detection of a wide
range of tumour types. Promoter hypermethylation of CpG islands
in tumour-suppressor genes, for example, BRCA1, occurs fre-
quently in tumorigenesis. Tumour treatment with DNMTis, such
as 5-aza-20-deoxycytidine, combined with HDACis has achieved
moderate success in several patients with acute promyelocytic
leukaemia (Lo Coco et al, 2002).
Finally, it seems likely, if not certain, that aberrant phosphory-
lation and ADP-ribosylation of histones also play a role in
tumorigenesis, since Aurora B kinase has been shown to
phosphorylate serines in H3 (Figure 1A) and act as an oncogene
in human cancer and mice studies (reviewed in Balmain et al,
2003). Additionally, increased ADP-ribosylation of histones and
nonhistone chromosomal proteins has been observed in oral
tumours (Das, 1993). Also, while most of the above studies have
focused attention on the major core histones, emerging evidence
suggests that histone variants themselves will hold critical
epigenetic information that distinguish it from what is carried by
the major histones. H2A.X, for example, is a dosage-sensitive
suppressor of oncogenic translocations and tumours in mice
(Bassing et al, 2003; Celeste et al, 2003), and, remarkably, this
histone variant is phosphorylated at a unique serine in its C-tail
(Ser139) in a pathway induced by DSB (see Figure 4B). The H3-like
variant CENP-A is specifically localised in centromeres, and
phosphorylation of serine 7 (Zeitlin et al, 2001) is implicated in
mitosis. A recent study showed that overexpression of CENP-A
leads to mis-targeting and is found in colorectal cancer tissues
(Tomonaga et al, 2003). Thus, a more generalised concept is
emerging that histone proteins, and their post-translational
‘fingerprints’ may well have direct links to human cancer.
Despite remarkable progress in this area, we are just beginning to
scratch the secrets of the histone ‘language’, and many more
mysteries remain to be solved. How do cells memorise the
epigenetic ‘code’ over many cell generations? And how to read
and understand this complex ‘code’, that is so different from the
genetic code, so that predictions can be made in the future about
the fate of a cell in specific situations. Taking one step further back,
we and others are beginning to favour the view that medical
genetics may well be neglecting epigenetics in other diseases with
complex and poorly understood origins that seem to not follow the
classical rules of Mendelian genetics (Beaudet, 2002). As we turn
the corner of the 50th birthday of the Watson/Crick DNA double
helix, we look forward to gaining insights into heritable mechan-
isms that operate outside of the DNA. In the epigenetic mechanisms
described here, the DNA remains essentially unaltered or ‘wild-
type’ in sequence. Thus, understanding how to manipulate its
expression (i.e. to de-silence tumour suppressors or to inactivate
oncogenes) in an epigenetic/chromatin context promises to lead to
exciting advances in our understanding of normal development as
well as pathological abnormalities leading to neoplasia.
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